An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

(2016) Sherry X. Yang et al.   CANCER TREATMENT REVIEWS

Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method

(2016) Shintaro Nakano et al.   Cardiology Journal

Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy

(2015) Yasuhiro Mitsui et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity

(2015) Gauri Akolkar et al.   Cardiovascular Ultrasound

A Prospective Randomised Phase III Clinical Trial Testing the Role of Prophylactic Cranial Radiotherapy in Patients Treated with Trastuzumab for Metastatic Breast Cancer — Anglo Celtic VII

(2015) P. Canney et al.   CLINICAL ONCOLOGY

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study

(2015) Xavier Pivot et al.   EUROPEAN JOURNAL OF CANCER

Antroquinonol from Antrodia Camphorata suppresses breast tumor migration/invasion through inhibiting ERK-AP-1- and AKT-NF-κB-dependent MMP-9 and epithelial-mesenchymal transition expressions

(2015) Wai-Theng Lee et al.   FOOD AND CHEMICAL TOXICOLOGY

A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study)

(2015) Kozo Kataoka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer

(2015) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

(2015) Karen A. Gelmon et al.   JOURNAL OF CLINICAL ONCOLOGY

Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474)

(2015) Julie K. Mason et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

(2015) Sara A Hurvitz et al.   LANCET ONCOLOGY

The prognostic value of phosphorylated Akt in breast cancer: a systematic review

(2015) Zu-Yao Yang et al.   Scientific Reports

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells

(2014) Mari Hosonaga et al.   CANCER SCIENCE

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer

(2014) Luis J. Schwarz et al.   JOURNAL OF CLINICAL INVESTIGATION

Co-targeting estrogen receptor and HER2 pathways in breast cancer

(2013) Arjun Mehta et al.   BREAST

HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

(2013) S. Ithimakin et al.   CANCER RESEARCH

Silencing MED1 Sensitizes Breast Cancer Cells to Pure Anti-Estrogen Fulvestrant In Vitro and In Vivo

(2013) Lijiang Zhang et al.   PLoS One

Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells

(2012) J. Cui et al.   CANCER RESEARCH

Med1 plays a critical role in the development of tamoxifen resistance

(2012) Arumugam Nagalingam et al.   CARCINOGENESIS

Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth

(2011) Zhong Chen et al.   EMBO JOURNAL

A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers

(2010) J. L. Parra-Palau et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation

(2010) P. Jiang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activity of fulvestrant in HER2-overexpressing advanced breast cancer

(2009) J. F. R. Robertson et al.   ANNALS OF ONCOLOGY

MED1 Phosphorylation Promotes Its Association with Mediator: Implications for Nuclear Receptor Signaling

(2008) M. Belakavadi et al.   MOLECULAR AND CELLULAR BIOLOGY